Form 4: Protagenic Therapeutics CFO Acquires Options in Company Stock

Alexander K. Arrow, Chief Financial Officer of Protagenic Therapeutics, acquired options to purchase 100,000 shares of the company's common stock on March 25, 2024.

Summary

• On March 25, 2024, Alexander K. Arrow, the Chief Financial Officer of Protagenic Therapeutics, acquired options to purchase 100,000 shares of PTIX common stock.
• The exercise price of these options is $1.74 per share.
• The options vest monthly over 36 months, starting from the grant date, and will fully vest upon a change of control.
• The expiration date for these options is March 25, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The CFO's acquisition of options may signal confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the CFO.

Key Dates

Keywords

Protagenic Therapeutics, PTIX, CFO, Alexander K. Arrow, stock options, Form 4, insider trading